In MRSA pneumonia, which agent may be preferred in patients with thrombocytopenia or high risk of nephrotoxicity?

• A. Linezolid
• B. Vancomycin
• C. Daptomycin
• D. Clindamycin

Answer: (A)

The main idea here is choosing an agent for MRSA pneumonia that provides reliable MRSA coverage and has a safer profile when kidney toxicity is a concern. Linezolid stands out because it treats MRSA effectively and penetrates the lungs well, with high oral bioavailability so you can switch from IV to oral easily. Importantly, it does not carry a risk of nephrotoxicity and does not require renal dose adjustment, making it a preferable option in patients where kidney toxicity risk is a major concern.

Vancomycin can be nephrotoxic and requires trough monitoring, which is a drawback in patients at risk for kidney injury. Daptomycin isn’t suitable for pneumonia because it is inactivated by pulmonary surfactant. Clindamycin can cover some MRSA strains but is less reliably effective in MRSA pneumonia due to variable coverage and penetration.

Note that linezolid can cause thrombocytopenia with longer courses, so platelets should be monitored if used for extended therapy, and watch for other hematologic or drug interaction risks.